Olmesartan medoxomil (OLM) is a frequently prescribed drug for the management of hypertension that works by blocking the angiotensin II receptor. OLM is classified as a class II medicine by the Biopharmaceutical Classification System (BCS) due to its weak solubility and bioavailability. The current work aims to create a self-micro-emulsifying drug delivery system (S-SMEDDS) to improve the solubility and availability of OLM. In this experiment, the liquid SMEDDS was formulated using the optimized mixture of carbitol, tween 20 and castor oil. The solid-SMEDDS formulation was developed by lyophilizing L-SMEDDS in the presence of mannitol in 2% w/v amount as a cryoprotectant. Evaluation and characterization of the generated freeze-dried powder was carried out using various techniques. The powder has excellent flow qualities, according to the results. Furthermore, the freeze-dried powder in vitro dissolution study was compared to the marketed drug and plain drug. The freeze-dried powder exhibited 98.55±0.015% drug release within 45 minutes, whereas the marketed formulation and plain drug displayed only 57.35±0.085 % and 39.42±0.051 % release respectively after 45 minutes. Results of in vitro dissolution investigation conclude that the freeze-dried powder form of S-SMEDDS of OLM boosts the solubility profile.